The survival prediction of hospitalized patients with COVID-19: the role of chitotriosidase level in peripheral blood
- 作者: Schelkanovtseva E.1, Isaev G.1, Mironova O.1, Balakhonov A.1, Skvortsov A.2, Nagornov I.3, Suvorov A.1, Fomin V.1, Panferov A.1
-
隶属关系:
- Sechenov First Moscow State Medical University (Sechenov University)
- Lomonosov Moscow State University
- Bochkov Medical Genetic Research Center
- 期: 卷 95, 编号 7 (2023)
- 页面: 543-547
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/148294
- DOI: https://doi.org/10.26442/00403660.2023.07.202280
- ID: 148294
如何引用文章
全文:
详细
Aim. To assess the relationship between plasma chitotiosidase (CHIT) level and mortality in hospitalized patients with COVID-19.
Materials and methods. 347 hospitalized patients with COVID-19 were enrolled in our single-center cohort prospective observational study. On the first day of hospitalization the patients were assessed by the level of CHIT in the venosus blood to addition to default laboratory examinations. The primary endpoint was all-cause death. The survival after hospital discharge were assessed via phone calls on 90 and 180 days since inclusion to the study (NCT04752085).
Results. Our study included 347 patients. The first symptoms appeared in 7 days [5; 7] before hospitalization; 283 (84.3%) patients had less than 50% of the involvement of the lung tissue to the inflammation process (CT 0–2); 36 (10.4%) patients had died since the start of our investigation; 30 (83.3%) of them died during hospitalization, others -no later than 60 days; 68 (19%) people didn’t answer during phone call. The survivor's activity of the enzyme in the deceased was significantly lower in compare to deceased patients (90.5 [40.2; 178.0] nmol/h/mL vs 180.0 [77.2; 393.2] nmol/h/mL; p=0.001). Survivor of the patients with a higher level of the activity of the CHIT (more than 171 nmol/h/mL) was statically significantly lower.
Conclusion. Rising of the CHIT's activity more than 171 nmol/h/mL might be an early independent predictor of the bad prognosis of the patients, who were hospitalized with COVID-19 infection.
作者简介
Ekaterina Schelkanovtseva
Sechenov First Moscow State Medical University (Sechenov University)
编辑信件的主要联系方式.
Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0001-9098-4098
аспирант каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowGeorgy Isaev
Sechenov First Moscow State Medical University (Sechenov University)
Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0002-4871-8797
ординатор каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowOlga Mironova
Sechenov First Moscow State Medical University (Sechenov University)
Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0002-5820-1759
канд. мед. наук, проф. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowAlexander Balakhonov
Sechenov First Moscow State Medical University (Sechenov University)
Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0002-1166-9856
аспирант каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowAlexey Skvortsov
Lomonosov Moscow State University
Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0001-8743-5207
ординатор фак-та фундаментальной медицины
俄罗斯联邦, MoscowIlya Nagornov
Bochkov Medical Genetic Research Center
Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0001-9368-1594
врач – лабораторный генетик
俄罗斯联邦, MoscowAleksandr Suvorov
Sechenov First Moscow State Medical University (Sechenov University)
Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0002-2224-0019
канд. мед. наук, гл. статистик НЦМУ «Цифровой биодизайн и персонализированное здравоохранение»
俄罗斯联邦, MoscowVictor Fomin
Sechenov First Moscow State Medical University (Sechenov University)
Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0002-2682-4417
чл.-кор. РАН, д-р мед. наук, проф., зав. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, MoscowAlexandr Panferov
Sechenov First Moscow State Medical University (Sechenov University)
Email: mar-shhelkanovceva@yandex.ru
ORCID iD: 0000-0002-4324-7615
канд. мед. наук, доц. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского
俄罗斯联邦, Moscow参考
- «Профилактика, диагностика и лечение новой коронавирусной инфекции 2019-nCoV». Временные методические рекомендации Министерства здравоохранения Российской Федерации. 2021; версия 12. Режим доступа: https://base.garant.ru/400738625/ Ссылка активна на 09.08.2022 [«Prevention, diagnosis and treatment of new coronavirus infection 2019-nCoV». Interim methodological recommendations of the Ministry of Health of the Russian Federation. 2021; version 12. Available at: https://base.garant.ru/400738625/ Accessed: 09.08.2022 (in Russian)].
- Gooday GW. Aggressive and defensive roles for chitinases. EXS. 1999;87:157-69. doi: 10.1007/978-3-0348-8757-1_11
- Lee CG, Da Silva CA, Cruz CSD, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Ann Rev Physiol. 2011;73:1. DOI:0.1146/ANNUREV-PHYSIOL-012110-142250
- Kanneganti M, Kamba A, Mizoguchi E. Role of chitotriosidase (chitinase 1) under normal and disease conditions. J Epithel Biol Pharmacol. 2012;5:1. doi: 10.2174/1875044301205010001
- Chang D, Sharma L, Cruz CSD. Chitotriosidase: a marker and modulator of lung disease. Eur Respir Rev. 2020;29:156. doi: 10.1183/16000617.0143-2019
- Sharma L, Amick AK, Vasudevan S, et al. Regulation and role of chitotriosidase during lung infection with Klebsiella pneumoniae. J Immunol. 2018;201(2):615-26. doi: 10.4049/JIMMUNOL.1701782/-/DCSUPPLEMENTAL
- Bennett D, Cameli P, Lanzarone N, et al. Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis. Respir Res. 2020;21(1):1-12. doi: 10.1186/s12931-019-1263-z
- Mazur M, Zielińska A, Grzybowski M, et al. Chitinases and Chitinase-Like Proteins as Therapeutic Targets in Inflammatory Diseases, with a Special Focus on Inflammatory Bowel Diseases. Int J Mol Sci. 2021;22(13):6966. doi: 10.3390/IJMS22136966
- Cakır G, Gumus S, Ucar E, et al. Serum chitotriosidase activity in pulmonary tuberculosis: response to treatment and correlations with clinical parameters. Ann Lab Med. 2012;32(3):184-9. doi: 10.3343/ALM.2012.32.3.184
- Kernan K, Carcillo J. Hyperferritinemia and inflammation. Int Immunol. 2017;29(9):401-9. doi: 10.1093/INTIMM/DXX031
- Feld J, Tremblay D, Thibaud S, et al. Ferritin levels in patients with COVID-19: A poor predictor of mortality and hemophagocytic lymphohistiocytosis. Int J Lab Hematol. 2020;42(6):773-9. doi: 10.1111/IJLH.13309
- Violi F, Cangemi R, Romiti GF, et al. Is Albumin Predictor of Mortality in COVID-19? Antioxid Redox Signal. 2021;35(2):139-42. doi: 10.1089/ARS.2020.8142